FOXP3 promotes tumor growth and metastasis by activating Wnt/β-catenin signaling pathway and EMT in non-small cell lung cancer
Shucai Yang(Southern Medical University Shenzhen Hospital), George G. Chen(Chinese University of Hong Kong), Chang Zou(Jinan University), Jing Du(Sichuan University), Calvin S.H. Ng(Johnson & Johnson (United States)), Yi Liu(Ewha Womans University), Tony Mok(Chinese University of Hong Kong), Shengli Yang(Shanghai Jiao Tong University), Mingyue Li(Utah State University), Lizhong Liu(Shenzhen University), Yujuan Dong(Chinese University of Hong Kong), Shanshan Wang(Henan University of Science and Technology), Malcolm J. Underwood(Bristol Royal Infirmary), Innes Y.P. Wan(Chinese University of Hong Kong), Xiang Long(Peking University Shenzhen Hospital)
Cited by 429
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k